AP-205™ Chimeric Antigen Receptor (CAR) NK Cells
Alphageneron is developing ‘off-the-shelf’ umbilical cord (UC) blood- and induced pluripotent stem cell (iPSC)-derived CAR-engineered NK (CAR NK) cell-based cancer therapeutics that target tumors expressing membrane Hsp70, and other (undisclosed) targets.
Gene editing of allogeneic CAR NK cells improves persistence, potency, and efficacy.